Aktiespararna
June 13, 2023

ALZECURE PHARMA
- Projects in Alzheimer's & Pain

Martin Jönsson, CEO

AlzeCure

Disclaimer

This presentation contains forward-looking statements regarding the Company's intentions, assessments, or expectations in respect of the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and possibilities as well as the market within which the Company operates. Forward-looking statements are statements which do not refer to historical facts and which typically contain words such as "considers", "expects", "predicts", "intends to", "estimates", "will", "can", "presumes", "should", "may" and, in each case, negations thereof or other similar expressions. The forward-looking statements in this presentation are based on different assumptions which, in several cases, are based on additional assumptions. Even if the Company considers the assumptions which are reflected in these forward-looking statements to be true, it cannot be guaranteed that they will in fact occur or that they are correct. Given that these assumptions are based on assumptions or estimates and that they are subject to risks and uncertainties, the actual result may, for many reasons, substantially deviate from what is stated in the forward-looking statements.

Such risks, uncertainties, eventualities, and other significant factors may lead to the actual events deviating substantially from the expectations that have been explicitly or implicitly provided for under this presentation through the forward-looking statements. The Company does not guarantee that the assumptions which the forward-looking statements in this presentation are based on are correct, and a reader/participant of this presentation should not unduly rely on the forward-looking statements contained herein. The information, opinions, and forward-looking statements which are either explicitly or implicitly presented herein, are only provided as of the day of this presentation and may be subject to change. Neither the Company nor anyone else undertakes to oversee, update, confirm or provide public notification in respect of any change of any forward-looking statement for the purpose of reflecting the actual events or circumstances which occurs in respect of the content of this presentation, unless required by law or Nasdaq First North Growth Market's rules for issuers.

AlzeCure

Agenda

- Who we are
- Focus areas
- Pipeline & the science
  - Progress, achievements & goals

AlzeCure

AlzeCure Pharma – in brief

- Working in **Alzheimer's Disease** (AD) and **Pain** – Hugh unmet medical need & multi-billion sales potential
- Spin-out from **AstraZeneca** – as a result of them ending their CNS projects
- Founded in **2016**, out of a research foundation sponsored by **Alzheimerfonden**
- **Experienced team** with extensive background within pharma industry
- Based at Novum Science Park, **Karolinska Institute**, Stockholm, Sweden

- Three project platforms with multiple **small molecule** candidates
  - **Alzstatin®** – An innovative preventive & disease-modifying treatment against Alzheimer's (AD)
  - **NeuroRestore®** – A novel first-in-class symptomatic treatment for cognitive disorders, e.g. AD
  - **Painless** – Innovative projects for osteoarthritic & neuropathic pain

- Listed on **Nasdaq First North Premier** Growth Market since Nov. 2018 (Ticker: ALZCUR)
- Market cap**: MSEK 394** (June 12 2023)
- Cash Position: **MSEK 54** (Q1 2023 interim report)

AlzeCure

Our Business Model

- We are a **Research & Development** company
- Research & **develop through early clinical phase** and then **to out-license** or partner on our projects
- Gain incomes through:
  - **Upfront payments**
  - **Milestone payments**
  - **Royalties** on sold products

AlzeCure

Small molecule drugs – AlzeCure's approach for increased success

DIFFERENCES BETWEEN SMALL MOLECULES & BIOLOGICS*

SMALL MOLECULE DRUG

LARGE BIOLOGIC

AlzeCure focus



Monoclonal antibody
c. 25,000 atoms

Additional benefits:
- Oral medications
- Low production costs
- …

Smaller molecules can have increased likelihood of penetrating the Blood Brain Barrier

*) Illustrative size

A pipeline of small-molecule programs

– Multiple candidates increase chance of success

Platform	Candidate	Indication	Research phase	Preclinical phase	Phase I	Phase II	Phase III
NeuroRestore®	ACD856	Alzheimer's Disease, Sleep disorders, Traumatic brain injuries Parkinson's disease					
	ACD857	Alzheimer's Disease					
Alzstatin®	ACD679	Alzheimer's Disease					
	ACD680	Alzheimer's Disease					
PainLess	ACD440	Neuropathic Pain					
	TrkA-NAM	Osteoarthritic Pain & other severe pain conditions					

Positive read-out Phase I trial
Safety, Tolerability & Target engagement

Selected new additional CD
ACD680

Positive read-out Phase IIa
Safety, Tolerability & Pain

Phase completed

Phase ongoing

AlzeCure

Close cooperation with leading experts & institutions

Professor Bengt Winblad
Karolinska Institute

Professor Maria Eriksdotter
Karolinska Institute

Professor Henrik Zetterberg
Sahlgrenska and UCL

Karolinska Institutet

GÖTEBORGS UNIVERSITET
SAHLGRENSKA AKADEMIN

UCL

AlzeCure

Our primary Focus area

Alzheimer's Disease

- EVERY FIVE SECOND a new person is diagnosed with Alzheimer's
- Costs the society more than oncology & cardiovascular diseases TOGETHER
- The patient population & costs are expected to TRIPLE in the next 30 years

AlzeCure

Tripling patient population – due to the aging population



- **50 million** people worldwide live with dementia …
- … and **doubling every 20 years**
- Alzheimer's accounts for 60 - 80% of all dementia cases

AlzeCure

Progress & Increased Activity in the Alzheimer's field

De-risking

- Validation of treatment approach: - Amyloid protein targeting
- Positive out-comes in clinical trials, - incl in phase III + approvals
- Vastly improved biomarkers & diagnostics identifying patients
  => increased probability of success in future studies

Increased investments

- Additional Big Pharma companies entering the field
- More funds and private equity investment in companies and projects, including by EQT
- ...

AlzeCure

Two Alzheimer's platforms - 1st-in-class potentials & future game-changers

MEETING NEEDS OF AD PATIENTS – ADRESSING SHORT TERM NEEDS WITH LONG-TERM BENEFITS

Preventive Disease-modifying therapy

Alzstatin®

MoA: Gamma-secretase modulator

Targeting Toxic Amyloid Production

- *Novel Oral Small Molecule*

Symptomatic & pot. Disease-modifying therapy

NeuroRestore®

MoA: Trk-PAM

Improving Neural & Cognitive Function

- *Novel Oral Small Molecule*

AlzeCure

Preventing or delaying Alzheimer's

Alzstatin®

MoA: Gamma-Secretes-Modulator

Targeting Toxic Amyloid Production

- *Novel Oral Small Molecule*

AlzeCure

DEVELOPMENT OF ALZHEIMER´S

The Amyloid cascade - Generating toxic and damaging fragments, including plaques, damaging neurons and brain structures

AlzeCure's GSM*
Alzstatin® reducing
Ab-42^ to diminishing
the build-up of toxic
fragments and plaque





=> STOP ALZHEIMER'S DEVELOP

*) GSM = Gamma Secretes Modulator. ^) AB-42 = Amyloid beta 42

AlzeCure

Alzheimer's Disease Modifier – Preventing or delay disease progression

ALZHEIMER'S DISEASE PROGRESSION



A-beta-42 - main culprit in Alzheimer's progression



found a way to limit A-beta−42 production

Alzstatin modulates the enzyme and thereby limits the A-beta-42 production and toxic clustering



*Alzstatin **targets the g-secretase***

AlzeCure

Brain status at intended treatment initiation

Target patient population - *Alzstatin® vs Antibodies*

Healthy brain at risk of Alzheimer's



Mild Alzheimer's

- The antibody Aduhelm has the indication, "Mild Alzheimer's disease"*, where the brain is already heavily damaged and the patient has cognitive symptoms.
- Alzstatin ® is targeting an earlier disease stage, identified by biomarkers and risk factors, with the intention to prevent or minimize brain damage.

*) Indication of Aduhelm® (aducanumab) & Leqembi® (lecanemab)

AlzeCure

How Alzstatin is expected to differ from the Antibodies*
- Key advantages



Small molecule therapy

- Small molecules generally pass much more readily across the BBB to its target site - the brain
- Provides a more cost-effective treatment for chronic use than biologics



Oral formulation => Home treatment

- Don’t need to go to the hospital once or twice a month for an infusion of the drug

Early treatment

- Taken before the brain is heavily damaged and the patient is diagnosed with cognitive decline and Alzheimer’s disease, which is the case for the antibody

Fewer side effects

- Not expected to have the side effects of brain oedema and brain micro-bleedings (ARIA)
  - => Is not expected to demand regular brain scans, => minimizing hospital visits and costs

*) E.g. Aduhelm (aducanumab), Leqembi (lecanumab), Donanemab

AlzeCure

Multiple target populations: - Preventive & Maintenance Therapy

- **Preventive therapy -** based on genetic risk factors* and biomarkers
  - Early stand-alone treatment before onset of symptoms and any major neurodegeneration occurring
  - Prevents build-up of amyloid – an early pathological feature of AD
  - Suitable for preventive therapy - as a “statin” for Alzheimer’s disease
  - Familiar forms of the disease (incl. Downs syndrome)
- **Maintenance therapy -** in patients with established Alzheimer’s
  - Potential for maintenance treatment after initial plaque clearance provided by monoclonal antibody treatment (as initially proposed by Lilly) e.g., with:
    - Lecanemab (Eisai/Biogen/Bioartic)
    - Donanemab (Lilly)
    - Remternetug (Lilly)

*) E.g. ApoE4

AlzeCure

Improving Learning & Memory Capabilities



NeuroRestore®

Trk-PAM

Improving Neuronal Function & Cognition

- *Novel Oral Small Molecule*

AlzeCure

NeuroRestore – to Improve Learning & Memory Capabilities



- AlzeCure's compounds act as **enhancers of neurotrophin, e.g. BDNF/NGF signalling**, and the broad effect profile in this specific biological pathway implies **multiple** possible **indications,** including, e.g.:
  - Alzheimer's disease,
  - Parkinson's disease,
  - Traumatic Brain injury
  - Depression
  - …

NeuroRestore - Cognitive Enhancer Improving Learning & Memory Capability

Stages of memory formation

LEARN

Transforming information into a form that can be stored in memory

STORE

Maintaining the encoded information in memory

REMEMBER

Re-accessing the information from the past which has been encoded and stored

NeuroRestore has in pre-clinical models shown that it can improve the ability to **learn** and **remember** information, so the information is accurately recollected when needed.

Finalized phase I – Preparing for phase II

- Shown safety & tolerability, as well as target engagement

AlzeCure

NEW DATA

Potential also for Disease Modification

=> Improving Brain Health

NeuroRestore ACD856:

- ✓ **Increases the levels of BDNF** in cortical neurons
- ✓ **Improves mitochondrial function** and **acts neuroprotective** in an energy-deprived neurotoxicity assay
- ✓ **Induces neurite outgrowth** in cells at concentrations similar to what is found in CSF in the clinical study
- ✓ **Increases levels of synaptic markers** in cells
- ✓ Shows **long-term plasticity effects** after repeated dosing



Opens potentially ups for **new additional benefits & usage** of ACD856 & the NeuroRestore compounds

AlzeCure

Press release

NeuroRestore ACD856 – Candidate in clinical trials
- Patent in the US to **2039**

AlzeCure receives US patent for NeuroRestore ACD856

September 8, 2022

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the United States Patent Office (USPTO) has issued a patent covering ACD856, which is being developed against Alzheimer's disease and other disorders with cognitive impairment.

USPTO has announced that they have now approved the company's patent application in the US, which refers to ACD856, the leading drug candidate in the NeuroRestore platform, which is being developed against Alzheimer's disease. The patent number is US 11,352,332 and the patent is valid until 2039.

ACD856 and other substances in the NeuroRestore platform stimulate several important signaling systems and signaling molecules in the brain such as BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which can lead to improved cognition. Previous preclinical studies have shown that AlzeCure's drug candidates strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions. New preclinical results also show potential neuroprotective and disease-modifying effects with these substances. The biological mechanism behind NeuroRestore enables several indications, such as Alzheimer's and Parkinson's disease, but also depression.

https://www.alzecurepharma.se/en/alzecure-receives-us-patent-for-neurorestore-acd856/

AlzeCure

Our platform PAINLESS – Targeting unmet medical needs within pain

Osteoarthritis & severe pain conditions

> 300 million patients

Project: **TrkA-NAM**

Neuropathic pain*

600 million patients

Project: **ACD440**

*) Neuropathic pain = Pain initiated or caused by a primary lesion or dysfunction in the somatosensory nervous system

AlzeCure

ACD440 – Novel TRPV1 antagonist in phase 2 for neuropathic pain

PROJECT OVERVIEW

Emanates from Big Pharma

- Approximately **SEK 200m** already **invested** on project development
- **Mode of action confirmed** in several Phase 1 clinical trials
- Synthesized compound and formulation developed

VR1 – optimized for local delivery

- The vanilloid receptor subtype 1 (TRPV1) is expressed in nociceptive sensory neurons
- TRPV1 is upregulated in the skin of patients with neuropathic pain
- **Strong scientific support** for peripheral/local treatment with TRPV1 antagonists

Positive clinical trial results

- Developed **topical formulation**
- **Clinical trial** with topical formulation was initiated and **successfully finalized**
- Phase 1b study addressed **safety, tolerability & efficacy – POSITIVE OUTCOMES**

Received **feedback from FDA**
- **Started phase 2a clinical trial,** June 2022
- **POSITIVE phase 2a** – Safety, tolerability & pain

AlzeCure

NEW DATA*

POSTITIV phase 2a read-out in peripheral neuropathic pain

- ACD440 demonstrated **positive proof-of-mechanism** (PoM) results in patients with **chronic** peripheral neuropathic **pain**, i.e. the drug candidate has an effect on the intended target mechanism
- A **significant pain relieving effect** was observed on pain induced by cold and heat. This temperature hypersensitivity is very common in the skin area, where the patients have their neuropathic pain, and is a major problem in everyday life for these individuals
- ACD440 was **well tolerated** as a topical gel on the skin
- The outcomes are **in line with previous reported** phase Ib **results**.
- The results **supports** shows good suitability for **continued clinical development**, i.e. as a local treatment against neuropathic pain conditions.

* May 24, 2023

AlzeCure

Neuropathic pain - Fast growing market

- The most valuable segment within the pain indications
- Poorly served patients
- Huge demand for better drugs

2020
$11 billions

CAGR to 2027
12.9% => **$25 billions**

The Neuropathic Pain market was valued at $10,8 billion in 2020 globally and is forecast to reach $25,2 billions by 2027, at a Compound Annual Growth Rate (CAGR) of 12,9%

GlobalData, Global Pain Therapeutics Market Overview, May 2021

AlzeCure

Key milestones & activities in 2023

- **Progress Alzstatin® ACD680** into the next phase, pre-clinical development
- Prepare **pre-IND** meeting on **NeuroRestore® ACD856** with **FDA** for next clinical study
- **Advance Painless TrkA-NAM** into pre-clinical safety testing towards a clinical candidate
- **Out-license or partner** on one of AlzeCure´s projects in the **Alzheimer's or Pain area**
- **Deliver** clinical **phase 2a study results** from with **Painless ACD440** in neuropathic pain

AlzeCure

Key investment highlights in AlzeCure

- Targeting areas of **huge unmet medical needs**
- **Strong team** with extensive experience and track record – from idea to clinic
- **Platforms with first-in-class properties** and potential **game-changers**
- **Parallel investments** in several candidates and potent **follow-up programs**
- **Multi-billion dollar** market **opportunities**
- Evolved from a Discovery into a **phase II company**

AlzeCure

Karolinska Institutet Novum Science Park
Hälsovägen 7, 141 57 Stockholm
SWEDEN

www.alzecurepharma.com

AlzeCure